ARX's CoSign Digital Signatures are SAFE-BioPharma Certified

Share Article

ARX (Algorithmic Research), a leading provider of digital signatures (standard electronic signatures) that ensure document integrity, announced today that CoSign®, its digital signature solution,has been certified by SAFE-BioPharma™. CoSign is the most widely used digital signature technology in the BioPharma industry.

News Image
CoSign's certification provides the level of confidence SAFE-BioPharma members seek in implementing SAFE-BioPharma solutions. This is truly a win-win development for both ARX and SAFE-BioPharma

ARX (Algorithmic Research), a leading provider of digital signatures (standard electronic signatures) that ensure document integrity, announced today that CoSign®, its digital signature solution,has been certified by SAFE-BioPharma™. CoSign is the most widely used digital signature technology in the BioPharma industry.
"This advancement not only enables companies to implement the strong user authentication put forth by SAFE-BioPharma, but also eliminates tokens, smartcards, and proprietary software, for substantial cost savings of 75 to 90 percent," said Rodd Schlerf, ARX Life Sciences and Healthcare Manager.
CoSign's centralized digital signature (PKI-based) design enables the signer's credentials to be accessed centrally from any network or web portal in any location. In addition to the speed and security with which digital signatures can be obtained, CoSign establishes a legally-binding audit trail.
"CoSign's certification provides the level of confidence SAFE-BioPharma members seek in implementing SAFE-BioPharma solutions. This is truly a win-win development for both ARX and SAFE-BioPharma," said Mollie Shields-Uehling, President and CEO, SAFE-BioPharma Association.
By agreeing to SAFE-BioPharma's credentialing standards, pharmaceutical companies reduce the cost and duration of business processes, speeding product development.

About SAFE-BioPharma Association:
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Amgen (NASDAQ: AMGN), AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, visit http://www.safe-biopharma.org.

About CoSign®:
The CoSign approach means digital signature standards and efficiencies across your operations. Signing and sealing documents with CoSign immediately expedites business processes, reduces costs, increases security and enables organizations to comply with diverse regional and industry regulations. CoSign works with all major applications and document formats including: Microsoft® Word, Excel®, Outlook®, Adobe® PDF, TIFF, AutoCAD®, InfoPath®, Lotus Forms, and many more). CoSign signatures are being used by hundreds of thousands of users in Enterprise, B2B and B2C processes, to learn why please see our white papers and product details at arx.com/products/cosign-digital-signatures.php.

About ARX (Algorithmic Research):
ARX has over 20 years of experience assisting banking, financial services, life sciences, healthcare, governmental organizations and commercial sectors to secure and streamline their business processes and transactions.

For more information, please visit arx.com.

CoSign® is a registered trademark of Algorithmic Research, Ltd. All other trade names and trademarks are the property of their respective holders.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Shirrah Friedman
Visit website